Kistarcsai Flor Ferenc Korhaz — Clinical Trial Site

43 Registered trials

10 Currently recruiting

Organisation

Kistarcsai Flor Ferenc Korhaz

Location

Kistarcsa, Hungary

Identifier

ORG-100041930

Address

Semmelweis Ter 1, 2143, Hungary

Departments

-
#2103: Neurológiai es Stroke Osztály
#6500: Deparment of Neurology
3610: Neurologia es Stroke Osztaly
5. sz. Belgyógyászati Osztály
5th Department of Internal Medicine
6009: Reumatológia és Fizioterápiás osztály
7806: V. Belgyógyászat
Department for Rheumatology and Physiotherapy
Department of Neurology and Stroke
Department of Rheumatology and Physiotherapy
Flor Ferenc Korhaz
HU10003: Reumatológiai és Fizioterápiás Osztály
II. Belgyógyászat - Angiológia
II. Belgyogyaszati Osztaly Angiologia
N/A
NA
Neurológia és Stroke Osztály
Neurology
Reumatológia
Reumatológiai és Fizikoterápiás Osztály
Reumatológiai és Fizioterápiás Osztály
Reumatológiai és Fiziotherápiás osztály
Reumatológiai-és Fizióterápiás Osztály
Sebészeti Osztály
V. Belgyogyaszat
V. Belgyógyászati osztály

Clinical trials at this site (43)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w… Recruiting

2025-522542-40-00 Acute Ischemic Stroke 5 2026-06-19
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting

2025-521416-19-00 Recurrence of Clostridioides difficile Infection 4 2026-03-12
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting

2024-517614-14-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-11-28
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

2024-515979-35-00 Generalized Myasthenia Gravis 5 2025-11-13
International study to compare the efficacy and safety of chondroitin sulfate 800 mg tablets of two different origins (bovine versus marine)… Recruiting

2024-516337-12-00 Knee osteoarthritis with moderate to severe pain 5 2025-08-07
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici… Ended

2025-521127-73-00 Relapsing forms of Multiple Sclerosis 5 2025-09-12
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc… Ended

2023-509320-17-00 non-radiographic axial spondyloarthritis 6 2023-03-28
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506257-37-00 Active Psoriatic Arthritis 5 2021-10-29
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended

2022-502609-14-00 Relapsing multiple sclerosis (RMS) 5 2020-12-09
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24